Shots:
- J&J has reported the topline P-IIb (JASMINE) trial data assessing Imaavy (nipocalimab) vs PBO in 228 adults with SLE, along with the initiation of the P-III program
- Trial met its 1EP with higher SRI-4 composite response at Wk. 24, plus achieved secondary & exploratory endpoints, incl. those indicating the potential of nipocalimab for steroid sparing; full results to be presented at a future congress
- Nipocalimab is an mAb that blocks FcRn to lower circulating IgG levels, aiming to reduce disease-causing antibodies while preserving normal adaptive & innate immune function
Ref: J&J | Image: J&J | Press Release
Related News: J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
